ArticleThe Journal of clinical endocrinology and metabolism2021
18F-FDG-PET/CT Evaluation of Indeterminate Adrenal Masses in Noncancer Patients.
Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Guideline
- American Association of Clinical Endocrinology Consensus Statement on Management of Multiple Endocrine Neoplasia Type 1.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025Guideline
- Differentiation of adrenal metastases and adenomas based on clinical characteristics, deep learning features, and radiomics features derived from ultrasound imaging.BMC medical imaging · 2026Article
- An interpretableFrontiers in oncology · 2025Article
- [18Endocrine · 2025Article
- Recent Development of CXCR4-Targeted Nuclear Medicine Research in Adrenocortical Tumors.Mini reviews in medicinal chemistry · 2025Review
- Alterations inMolecular imaging and radionuclide therapy · 2023Article
- Challenges and controversies in adrenal surgery: A practical approach.Current problems in surgery · 2023Article
- Prediction of 2-[Cancers · 2023Article
- Review of Diagnostic Modalities for Adrenal Incidentaloma.Journal of clinical medicine · 2023Review
- Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant adrenal masses.European journal of endocrinology · 2021Article
- Primary adrenal tuberculosis infection in patients with Behcet's disease presenting as isolated adrenal metastasis byGland surgery · 2021Article
- Approach to the Patient With Adrenal Incidentaloma.The Journal of clinical endocrinology and metabolism · 2021Review
- Review
- Histiocytosis Presenting as Bilateral Adrenal Masses: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
contextAdrenal tumors in noncancer patients are common.
objectiveEvaluate performance of 18F-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG-PET/CT) in distinguishing between benign and malignant adrenal tumors.
designRetrospective chart review 2010-2019.
settingAcademic institution. PATIENTS: One hundred and seventeen noncancer patients, defined as having no history of cancer or with cancer in remission for ≥5 years, completed 18F-FDG-PET/CT to evaluate adrenal masses, with pathologic diagnoses or imaging follow-up (≥12 months).
intervention18F-FDG-PET/CT of 117 indeterminate adrenal masses.
main outcome measuresReceiver operator characteristic curve of the ratios of adrenal lesion standardized uptake value (SUV)max to liver SUVmean and of adrenal lesion SUVmax to aortic arch blood pool SUVmean were constructed.
resultsSeventy benign and 47 malignant masses (35 adrenocortical carcinomas [ACCs], 12 adrenal metastases) were identified. Malignant masses had higher median liver SUV and blood pool SUV ratios than benign masses (6.2 and 7.4 vs 1.4 and 2.0, P < .001). Median liver and blood pool SUV ratios of ACC (6.1 and 7.3, respectively) and metastases (6.7 and 7.7, respectively) were higher than those of than adenomas (1.4 and 2.2, P < .05 for all comparisons). Optimal liver SUV ratio to discern between benign and malignant masses was 2.5, yielding 85% sensitivity, 90% specificity, and 7 false negative results (including 3 ACCs). Optimal blood pool SUV ratio was 3.4, yielding 83% sensitivity, 90% specificity, and 8 false negative results (including 4 ACCs).
conclusionWhen used in conjunction with other clinical assessments, 18F-FDG-PET/CT can be a valuable tool in evaluating adrenal masses in noncancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.